As part of the recent meeting "Current Perspectives in Acid Inhibitory Therapy" held at Yale University School of Medicine, a large group of experts met to discuss and debate a number of unsolved issues with regard to Helicobacterpylori infection in man. The discussion leaders were G.N.J. Tytgat and I.N J. Freston stated that there was probably no relationship of H. pylori to gastroesophageal reflux disease. The organism does not inhabit esophageal epithelium and, when present in Barrett's epithelium, does not appear to be associated with an inflammatory response. He suggested that H. pylori may extend in the proximal stomach with time, particularly with ppIc therapy, and may eventually interfere with LES function. There are also anecdotal reports of symptomatic remissions in patients with mild GERD after H. pylori eradication, and he speculated that this may be linked to resolution in gastrin levels following H. pylorn eradication. He did not think gastrin per se has an effect on the LES, but that the effect of gastrin on acid secretion may be relevant. Alternatively, some patients develop GERD symptoms after successful cure of the infection. Attention was drawn to the not infrequent finding of a fall in pH (from around 1.4 or 1.5 to 1.3) following H. pylori eradication. Whether this increased acidity is contributing in people who do not necessarily have frank esophagitis but have an acid sensitive esophagus requires further study. In addition, some patients do gain weight after H. pylori cure, which may also favor GERD manifestation. Finally it was noted that there are some patients with GERD in whom H. pylori eradication appears to be associated with increased acidity and a consequent increased requirement for PPIs.
LES, but that the effect of gastrin on acid secretion may be relevant. Alternatively, some patients develop GERD symptoms after successful cure of the infection. Attention was drawn to the not infrequent finding of a fall in pH (from around 1.4 or 1.5 to 1.3) following H. pylori eradication. Whether this increased acidity is contributing in people who do not necessarily have frank esophagitis but have an acid sensitive esophagus requires further study. In addition, some patients do gain weight after H. pylori cure, which may also favor GERD manifestation. Finally it was noted that there are some patients with GERD in whom H. pylori eradication appears to be associated with increased acidity and a consequent increased requirement for PPIs. aTo whom all correspondence should be addressed: G.N.J. 3Btgat, Academic Medical Centre, Department of Gastroenterology-Hepatology, Meibergdreef 9, 1105 AZ Amsterdam Zuidoost. Tel: 31-20-5663534; Fax: 31-20-6917033 . cAbbreviations: PPI, proton pump inhibitory; GERD, gastro-esophageal is not known whether it induces ulcers. F. Megraud was not aware of any case in which H. felis was cultured from the stomach. He noted that there were two sources of H. felis: the stomach of pets, especially cats and dogs, and the other the stomach of pigs. They have been studied using a PCR technique, and the organisms in cats and dogs are a subspecies. Possible differences in H. pylori in the antrum and body of the stomach in man were considered, but F. Megraud did not think that available data substantiated this. He stated that about 10 to 15 percent of people in developed countries may harbor two or more different strains of H. pylori. Mention was also made of other organisms that may cause inflammation in the stomach such as the Anisakis larvae in Japan which may also produce gastric metaplasia and lead to carcinoma in situ, Giardia or Candida which may colonize a pre-existing ulcer, and HSV-I. The suggestion was made that herpes (HSV-I) should perhaps be considered in patients with non-H. pylori non-NSAID-associated ulcers.
Both G. Tytgat and F. Megraud felt that other PPIs were as effective as omeprazole in enhancing antibiotic efficacy. It was noted that lansoprazole has a higher MIC than omeprazole against H. pylori, and F. Megraud suggested that reported differences may be linked to differences in the percentage of strains resistant to antibiotics. I.N. Marks drew attention to the initial perception that omeprazole was more effective than other PPIs in enhancing antibiotic efficacy. The early lansoprazole/amoxycillin data was appreciably lower than the 80 to 90 percent eradication rates claimed with omeprazole/amoxycillin combinations at the time. Against the latter background, the lansoprazole/amoxycillin, and for that matter, the pantoprazole/amoxycillin data of less than 45 percent seemed dismal. This led to the perception that the omeprazole/amoxycillin combination was the treatment of choice. It was only later than one appreciated that the omeprazole/amoxycillin eradication rates varied from 30 to 80 percent, and that the rates in most of the Western world and elsewhere, other than select centers in Germany, were in the region of 40 to 60 percent. R.H. Hunt concurred and indicated that his meta-analysis of omeprazole/amoxycillin data averages 61 percent. He stated that omeprazole/clarithromycin dual therapy was more predictable, with an average eradication rate of 71 percent. He cited data suggesting that omeprazole increases the concentration of clarithromycin in the gastric juice and in the antrum, but not the body of the stomach. This contrasts with data suggesting that the concentration of amoxycillin in the gastric mucosa is higher at a low pH. fundus, presumably to find a more acid environment, as a specific PPI effect. The possibility of this being due to a non-specific pH change was supported by the reportedly good ranitidine/antibiotic data. The allegedly delayed gastric emptying with H2 blockers or PPIs, allowing a prolonged antibiotic dwell time in the stomach, should also be considered.
Attention was then focused on the need to test for the presence of H. pyloni before and after eradication therapy. The need to test in a patient with duodenal ulcer was unclear since the chances of finding H. pylori negative is of the order of three or rour percent; not much different from the chances of finding a false H. pylori negative result. However, H. pylori testing should be done at the research or academic level where cost is not a factor. H. pylori testing after eradication therapy is warranted in complicated ulcer disease, but probably not in other patients -particularly in those treated with the newer eradication strategies which assure an eradication rate of over 85 to 90 percent.
